Skip to main content
Top
Published in: BMC Gastroenterology 1/2020

Open Access 01-12-2020 | Fatty Liver | Research article

Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis

Authors: Xuefeng Ma, Shousheng Liu, Jie Zhang, Mengzhen Dong, Yifen Wang, Mengke Wang, Yongning Xin

Published in: BMC Gastroenterology | Issue 1/2020

Login to get access

Abstract

Background

ALT value is often used to reflect the hepatic inflammation and injury in NAFLD patients, but many studies proved that ALT values were normal in many NAFLD patients. The aim of this study was to identify the summarized proportion of NAFLD patients with normal ALT value in the overall NAFLD patients.

Methods

Electronic databases PubMed, EMBASE, Ovid, and the Cochrane Library were searched for potential studies published from January 1, 2000 to September 30, 2019. Studies that have reported the number of NAFLD or NASH patients with normal and abnormal ALT value were included and analyzed. Abstracts, reviews, case reports, and letters were excluded.

Results

A total of 11 studies with 4084 patients were included for assessing the summarized proportion of NAFLD patients with normal ALT in overall NAFLD patients. As the results shown, the summarized proportion of NAFLD patients with normal ALT value in overall NAFLD patients was 25% (95%CI: 20–31%) which was calculated by the random-effects model. The summarized proportion of NASH patients with normal ALT value in overall NASH patients was 19% (95%CI: 13–27%). Subgroup analysis includes region, study type, diagnostic method, and group size were conducted to investigate the resource of heterogeneity in the summarized proportion of NAFLD and NASH patients with normal ALT value.

Conclusions

25% NAFLD patients and 19% NASH patients possess the normal ALT value in the clinical manifestation. The value of ALT in the clinical diagnosis of NAFLD and NASH remains need be further testified.
Literature
1.
go back to reference Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862–73.CrossRef Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862–73.CrossRef
2.
go back to reference Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896–904.CrossRef Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896–904.CrossRef
3.
go back to reference Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.CrossRef Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.CrossRef
4.
go back to reference Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389–98.CrossRef Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389–98.CrossRef
5.
go back to reference Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.CrossRef Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.CrossRef
6.
go back to reference Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol. 2017;23:6571–92.CrossRef Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol. 2017;23:6571–92.CrossRef
7.
go back to reference Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679–89.CrossRef Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679–89.CrossRef
8.
go back to reference Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Ther Adv Gastroenterol. 2011;4:249–63.CrossRef Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Ther Adv Gastroenterol. 2011;4:249–63.CrossRef
9.
go back to reference Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5:1544–60.CrossRef Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5:1544–60.CrossRef
10.
go back to reference Kim WR, Flamm SL, Di Bisceglie AM, et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47:1363–70.CrossRef Kim WR, Flamm SL, Di Bisceglie AM, et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47:1363–70.CrossRef
11.
go back to reference Amarapurka DN, Amarapurkar AD, Patel ND, et al. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann Hepatol. 2006;5:30–3.CrossRef Amarapurka DN, Amarapurkar AD, Patel ND, et al. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann Hepatol. 2006;5:30–3.CrossRef
12.
go back to reference Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–54.CrossRef Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–54.CrossRef
13.
go back to reference Sheng X, Che H, Ji Q, et al. The Relationship Between Liver Enzymes and Insulin Resistance in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease. Horm Metab Res. 2018;50:397–402.CrossRef Sheng X, Che H, Ji Q, et al. The Relationship Between Liver Enzymes and Insulin Resistance in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease. Horm Metab Res. 2018;50:397–402.CrossRef
14.
go back to reference Umehara T. Nonalcoholic fatty liver disease with elevated alanine aminotransferase levels is negatively associated with bone mineral density: Cross-sectional study in U.S. adults. PLoS One. 2018;13:e0197900.CrossRef Umehara T. Nonalcoholic fatty liver disease with elevated alanine aminotransferase levels is negatively associated with bone mineral density: Cross-sectional study in U.S. adults. PLoS One. 2018;13:e0197900.CrossRef
15.
go back to reference Sun DQ, Zheng KI, Xu G, et al. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. Liver Int. 2019. Sun DQ, Zheng KI, Xu G, et al. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. Liver Int. 2019.
16.
go back to reference Barusrux S, Nanok C, Puthisawas W, et al. Viral hepatitis B, C infection and genotype distribution among cholangiocarcinoma patients in northeast Thailand. Asian Pac J Cancer Prev. 2012;13(Suppl):83–7.PubMed Barusrux S, Nanok C, Puthisawas W, et al. Viral hepatitis B, C infection and genotype distribution among cholangiocarcinoma patients in northeast Thailand. Asian Pac J Cancer Prev. 2012;13(Suppl):83–7.PubMed
17.
go back to reference Lee CH, Hsieh SY, Chang CJ, et al. Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers. J Gastroenterol Hepatol. 2013;28:122–7.CrossRef Lee CH, Hsieh SY, Chang CJ, et al. Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers. J Gastroenterol Hepatol. 2013;28:122–7.CrossRef
18.
go back to reference Ioannidis JPA, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. Can Med Assoc J. 2007;176:1091–6.CrossRef Ioannidis JPA, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. Can Med Assoc J. 2007;176:1091–6.CrossRef
19.
go back to reference G . A . W e l l s BShea, D . O ’ C o n n e l l e t a l The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. 2012. G . A . W e l l s BShea, D . O ’ C o n n e l l e t a l The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. 2012.
20.
go back to reference R-Core-Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. 2017. R-Core-Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. 2017.
21.
go back to reference Mofrad P. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–92.CrossRef Mofrad P. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–92.CrossRef
22.
go back to reference Amarapurkar DN, Patel ND. Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values. Trop Gastroenterol. 2004;25:130–4.PubMed Amarapurkar DN, Patel ND. Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values. Trop Gastroenterol. 2004;25:130–4.PubMed
23.
go back to reference Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology. 2008;48:792–8.CrossRef Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology. 2008;48:792–8.CrossRef
24.
go back to reference Uslusoy HS, Nak SG, Gülten M, et al. Non-alcoholic steatohepatitis with normal aminotransferase values. World J Gastroenterol. 2009;15.CrossRef Uslusoy HS, Nak SG, Gülten M, et al. Non-alcoholic steatohepatitis with normal aminotransferase values. World J Gastroenterol. 2009;15.CrossRef
25.
go back to reference Wong VW, Wong GL, Tsang SW, et al. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther. 2009;29:387–96.CrossRef Wong VW, Wong GL, Tsang SW, et al. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther. 2009;29:387–96.CrossRef
26.
go back to reference McPherson S, Anstee QM, Henderson E, et al. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? Eur J Gastroenterol Hepatol. 2013;25:652–8.CrossRef McPherson S, Anstee QM, Henderson E, et al. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? Eur J Gastroenterol Hepatol. 2013;25:652–8.CrossRef
27.
go back to reference Verma S, Jensen D, Hart J, et al. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013;33:1398–405.CrossRef Verma S, Jensen D, Hart J, et al. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013;33:1398–405.CrossRef
28.
go back to reference Maximos M, Bril F, Portillo Sanchez P, et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology. 2015;61:153–60.CrossRef Maximos M, Bril F, Portillo Sanchez P, et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology. 2015;61:153–60.CrossRef
29.
go back to reference Isaksen VT, Larsen MA, Goll R, et al. Hepatic steatosis, detected by hepatorenal index in ultrasonography, as a predictor of insulin resistance in obese subjects. BMC Obes. 2016;3:39.CrossRef Isaksen VT, Larsen MA, Goll R, et al. Hepatic steatosis, detected by hepatorenal index in ultrasonography, as a predictor of insulin resistance in obese subjects. BMC Obes. 2016;3:39.CrossRef
30.
go back to reference Martin-Rodriguez JL, Gonzalez-Cantero J, Gonzalez-Cantero A, et al. Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy. Medicine (Baltimore). 2017;96:e6770.CrossRef Martin-Rodriguez JL, Gonzalez-Cantero J, Gonzalez-Cantero A, et al. Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy. Medicine (Baltimore). 2017;96:e6770.CrossRef
31.
go back to reference Tomizawa M, Kawanabe Y, Shinozaki F, et al. Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Rep. 2014;2:633–6.CrossRef Tomizawa M, Kawanabe Y, Shinozaki F, et al. Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Rep. 2014;2:633–6.CrossRef
Metadata
Title
Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis
Authors
Xuefeng Ma
Shousheng Liu
Jie Zhang
Mengzhen Dong
Yifen Wang
Mengke Wang
Yongning Xin
Publication date
01-12-2020
Publisher
BioMed Central
Keyword
Fatty Liver
Published in
BMC Gastroenterology / Issue 1/2020
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-020-1165-z

Other articles of this Issue 1/2020

BMC Gastroenterology 1/2020 Go to the issue